[go: up one dir, main page]

WO2025099684A1 - Phage fonctionnalisé pour le traitement de l'acné - Google Patents

Phage fonctionnalisé pour le traitement de l'acné Download PDF

Info

Publication number
WO2025099684A1
WO2025099684A1 PCT/IB2024/061130 IB2024061130W WO2025099684A1 WO 2025099684 A1 WO2025099684 A1 WO 2025099684A1 IB 2024061130 W IB2024061130 W IB 2024061130W WO 2025099684 A1 WO2025099684 A1 WO 2025099684A1
Authority
WO
WIPO (PCT)
Prior art keywords
functionalized
bacteriophage
phage
acne
isotretinoin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/061130
Other languages
English (en)
Inventor
Laura Tatiana Camacho Rodríguez
Diego Alexander Gamba Sánchez
Martha Josefina VIVES FLOREZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de los Andes Colombia
Original Assignee
Universidad de los Andes Colombia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de los Andes Colombia filed Critical Universidad de los Andes Colombia
Publication of WO2025099684A1 publication Critical patent/WO2025099684A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Definitions

  • the present disclosure relates to the general field of phage therapy, particularly to phage therapy applied for the treatment of acne and more particularly to the use of a phage functionalized with pharmacologically active molecules, with properties of interest for the target tissue for the treatment of acne.
  • the functionalized phage of the present disclosure has the additional advantage of targeting active molecules to the specific tissue colonized by bacteria.
  • Acne is a skin condition in which hair follicle obstruction occurs due to 4 pathophysiological factors: infection by Cutibacterium acnes. inflammation, sebum overproduction, and hyperkeratosis.
  • Disease treatment involves using oral antibiotics (tetracyclines, erythromycin), systemic retinoids (isotretinoin) or antiandrogens (spironolactone) in women with hormonal acne. It may also include the use of topical medicines, such as benzoyl peroxide, salicylic acid, topical retinoids, such as tretinoin or adapalene, as well as topical antibiotics, such as clindamycin or erythromycin. In some cases, however, the effectiveness of this treatment may vary due to disease complexity and individual differences in each person, considering that one of the key factors in treatment is compliance. The latter is mainly affected by the adverse effects of the medicines employed.
  • bioconjugates with aggregation-induced emission property that are active in photodynamic inactivation to generate a type of bioconjugate capable of targeted imaging and synergistic destruction of certain bacterial species.
  • the bioconjugates disclosed herein have the ability to generate an inherited orientation of the bacteriophage that allows them to specifically recognize the target bacteria. They are also described as potent photosensitizers in situ producing high-efficiency reactive oxygen species under white light irradiation, achieving selective selection and elimination of antibioticsensitive multi-resistant bacteria.
  • patent US2014/0030697A1 refers to methods, reagents, and kits for the functionalization of proteins present on the surface of viral particles, e.g., bacteriophages, using sortase-mediated transpeptidation reactions. It also discloses methods for conjugating an agent, e.g., a detectable tag, a binding agent, a click chemistry identifier, or a small molecule to a surface protein of a viral particle.
  • an agent e.g., a detectable tag, a binding agent, a click chemistry identifier, or a small molecule to a surface protein of a viral particle.
  • kits comprising reagents useful for the generation of functionalized viral particles, as well as precursor proteins comprising a sortase recognition fragment and viral particles comprising such precursor proteins, as well as nucleic acids encoding viral proteins comprising a sortase recognition fragment, and expression vectors comprising such nucleic acids.
  • the present disclosure refers to a biological-pharmacological formulation consisting of functionalized phages that allows targeting pharmacologically active molecules to a specific tissue colonized by bacteria.
  • the functionalized phages of the present disclosure correspond to lytic bacteriophages capable of infecting acne-causing bacteria, which are bound to one or more anti-acne molecules.
  • FIG. 1 Absorbance spectra showing bacteriophage-isotretinoin complex formation.
  • A. Spectral scanning of bacteriophage and isotretinoin molecules. The line identified by a triangle shows the curve corresponding to the mixture of bacteriophage and isotretinoin in a single sample without the process of isotretinoin-free molecule removal. The line identified by a dot shows the spectrum curve corresponding to an isotretinoin solution. The curve identified by a square shows the spectrum of the bacteriophage alone.
  • B. The curve shows the spectral scan corresponding to the formation of the bacteriophageisotretinoin complex, after being subjected to the processes of isotretinoin-free molecule removal.
  • FIG. 2 Results of the RT-qPCR technique to measure IL-ip relative expression of the experimental groups compared between points zero and 24 hours after inoculation with each treatment.
  • C corresponds to the group inoculated with C. acnes
  • CF corresponds to the group that was exposed to C. acnes and to the phage
  • CFI corresponds to the group inoculated with bacteria
  • phage-isotretinoin corresponds to the group inoculated with bacteriophage.
  • the statistical significance values for each experimental group are shown, wherein NS corresponds to non-significant, *P ⁇ 0.05 and **P ⁇ 0.01.
  • the present disclosure relates to a functionalized phage comprising a lytic bacteriophage against acne-associated bacteria, and an active molecule against acne having a carboxylic acid terminal group in its structure; wherein the bacteriophage and the active molecule are bound by a covalent bond without an additional spacer or ligand.
  • functionalized phage is understood to be a bacteriophage to which active molecules/medications are coupled, and wherein the bacteriophage acts as a vehicle for said medicines targeting them to the target tissue, thus producing high specificity against the pathogenic bacteria of each tissue.
  • Functionalized phages may be useful in the treatment of various infectious diseases that also benefit from the synergistic effect of medicines, e.g., acne, gastritis secondary to Helicobacter pylori, wound infections by Pseudomonas spp., pneumonia of bacterial origin, among others.
  • the present invention relates to functionalized phages for the treatment of acne, comprising lytic bacteriophages against acne-causing bacteria bound to molecules active against acne having a carboxylic acid terminal group in their structure.
  • a lytic bacteriophage is a bacteriophage capable of infecting and generating lysis in a bacteria of interest, i.e., they are phages that use the machinery of the bacterial cell after infecting the bacteria to manufacture their viral progeny and subsequently lyse the cell for the release of new phage particles.
  • Lytic bacteriophages have high host specificity and are harmless to adjacent tissues, as well as to other microorganisms that are part of the microbiota of these tissues. Therefore, lytic phages are considered an alternative and safe solution to combat bacterial pathogens, even those resistant to antibiotics.
  • lytic bacteriophages do not insert into the bacteria genome and have proteins with hydroxyl and amine residues exposed on their surface. Moreover, these bacteriophages are resistant to a pH range between 4 and 8 and are stable in a solution of dimethyl sulfoxide (DMSO).
  • DMSO dimethyl sulfoxide
  • the lytic bacteriophages are specific to bacteria involved in the development of acne, they specifically have the ability to infect the bacteria Cutibacterium acnes and more specifically strains of phylotypes IA1, IA2, IB and II of C. acnes.
  • such phages have species specificity and are unable to lyse any bacteria other than C. acnes, even though they have the ability to infect a wide range of bacterial strains within the species C. acnes.
  • the bacteriophages of the present disclosure have a genome with a nucleotide sequence that is selected from the sequences of SEQ ID NOs: 1, 2 and 3.
  • functionalize a bacteriophage is understood to be the process by which the surface of the bacteriophage is modified by binding to one or more molecules with exposed hydroxyl or amine residues.
  • the binding of the molecules to the phage surface is mediated by covalent bonds.
  • binding of lytic bacteriophage to the active molecule is performed by means of a covalent bond between the carboxylic acid residues of the molecule of interest and the amine or hydroxyl residues of the bacteriophage.
  • said covalent bond does not require an additional spacer or ligand or a catalyst to form and is stable at pH 8.
  • the covalent link is an ester or amide bond.
  • active molecules against acne correspond to drugs whose action in the treatment of acne corresponds to regulating sebum production, reducing follicle obstruction, and decreasing inflammation.
  • the active molecule against acne has carboxylic acid terminal groups in its structure and is stable when dissolved in a lytic phage-tolerating solvent.
  • drugs such as retinoid drugs
  • active molecules against acne are synthetic derivatives of vitamin A that bind to specific receptors and exert an action that regulates the proliferation and differentiation of keratinocytes while acting on the sebaceous gland, decreasing its size and activity.
  • Other drugs active against acne are alpha hydroxy acids, glycolic acid, salicylic acid, lactic acid, adapalene, azelaic acid, niacinamide, and antibiotics such as amoxicillin and lymecycline. These drugs have a terminal carboxylic acid group that makes them suitable candidates for active molecules to functionalize bacteriophages in the treatment of acne.
  • the following are considered active molecules against acne: retinoids, such as retinoic acid, acitretin, tretinoin, isotretinoin, and bexarotene.
  • the active retinoid against acne is isotretinoin.
  • the bacteriophage is functionalized with isotretinoin.
  • a lytic phage of C. acnes is functionalized in a concentration of approximately 2.2xlO 5 PFU/mL, with a solution of isotretinoin inDMSO at a 1 mM concentration.
  • EXAMPLE 1 Functionalization of bacteriophage with isotretinoin.
  • the phages were obtained from a collection of the C. J. Marinkelle Natural History Museum of the University of the Andes, and were cultured using the double agar layer technique, as follows: 200 pL of an inoculum of the host bacteria (C. acnes), in a concentration of between 10 8 - 10 9 CFU/mL, were taken and mixed by vortex with 100 pL of the initial bacteriophage stock. This bacteria-phage mixture was placed in a test tube with 2 mL New Soft agar, mixed again by vortex and poured onto a Petri dish with New Agar until the mixture was homogeneously distributed, and it was allowed to solidify for a few minutes.
  • C. acnes inoculum of the host bacteria
  • This bacteria-phage mixture was placed in a test tube with 2 mL New Soft agar, mixed again by vortex and poured onto a Petri dish with New Agar until the mixture was homogeneously distributed, and it was allowed to solidify for a few minutes.
  • the Petri dish was then incubated for 24 hours at 36 °C in an atmosphere of 10 to 15% CO2. Thereafter, the agar surface was scraped with a glass slide to collect only the superficial layer of New Soft agar containing the mixture of bacteria and bacteriophage. Then, the New Soft agar was mixed with 2 mL SM buffer for each Petri dish that was scraped into a conical centrifuge tube and allowed to stand for 24 hours. Finally, the mixture was centrifuged to separate agar from the solution containing the bacteriophages and was filtered using a 0.22 pm filter to obtain a new stock of the desired bacteriophage.
  • bacteriophages were obtained in a titer of between 1.0 x 10 11 and 1.0 x 10 13 PFU/mL and mixed with the active molecule in DMSO solution, at a concentration between 1.0 and 10 mM.
  • the mixture was made in a solution in SM buffer without gelatin with a pH between 7.8 and 8.
  • the above solution was incubated for a period between 24 and 48 hours at a temperature between 4 and 20 °C.
  • Active molecules that did not bind to the bacteriophage proteins were removed by means of ultracentrifugation, resuspending the functionalized bacteriophage and discarding the supernatant with the free active molecules.
  • removal was done by means of dialysis, using a membrane with a pore size of 14 kDa to retain the functionalized bacteriophage inside the membrane, while the active molecule was diluted in a washing solution. This process was carried out at a temperature of 37 °C.
  • the lytic activity of the bacteriophage was evaluated after functionalization by spot plating assays of the bacteriophage.
  • the bacteriophage viral titer was obtained with 2.2xl0 5 PFU/mL bound isotretinoin molecules, which is evidence that the bacteriophage retains its lytic activity after the functionalization process.
  • the anti-inflammatory capacity of the active molecule was evaluated after binding to the bacteriophage by adding this complex to a keratinocyte cell culture, and measuring the expression levels of an inflammation tag, interleukin ip (IL-ip), at 0 and 24 hours of exposure.
  • IL-ip interleukin ip
  • the results of this assay revealed that the group of keratinocytes that was exposed to phage-isotretinoin treatment shows significant differences between the two time points, with IL-ip significantly decreased after 24 hours of inoculation, compared to expression levels at zero hours of inoculation (FIG. 2), which means that phage-bound isotretinoin preserves its pharmacological activity.
  • the functionalized bacteriophages proved to have a synergistic effect since both the bacteriophage and the active molecule retained their activity after functionalization, which means that the results obtained are greater than those obtained by using each of the elements separately.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des phages fonctionnalisés avec des molécules pharmacologiquement actives pour le traitement de l'acné. De tels phages sont utiles dans le traitement de maladies infectieuses, car elles ciblent des substances pharmacologiques sur un tissu colonisé par des bactéries. Dans un mode de réalisation de la présente invention, les phages fonctionnalisés de la présente invention correspondent à des phages lytiques de la classe Caudoviricetes ayant une activité contre Cutibacterium acnes avec des molécules pharmacologiquement actives, spécifiquement avec de l'isotrétinoïne, ayant des propriétés d'intérêt pour le traitement de l'acné provoquée par Cutibacterium acnes, car ils agissent au niveau des glandes sébacées, réduisant l'inflammation, l'hyperproduction de sébum et la kératose.
PCT/IB2024/061130 2023-11-10 2024-11-08 Phage fonctionnalisé pour le traitement de l'acné Pending WO2025099684A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CONC2023/0015253A CO2023015253A1 (es) 2023-11-10 2023-11-10 Fago funcionalizado para tratamiento de acné
CONC2023/0015253 2023-11-10

Publications (1)

Publication Number Publication Date
WO2025099684A1 true WO2025099684A1 (fr) 2025-05-15

Family

ID=89853242

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/061130 Pending WO2025099684A1 (fr) 2023-11-10 2024-11-08 Phage fonctionnalisé pour le traitement de l'acné

Country Status (2)

Country Link
CO (1) CO2023015253A1 (fr)
WO (1) WO2025099684A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017200873A1 (fr) * 2016-05-15 2017-11-23 The Regents Of The University Of California Compositions et méthodes pour le traitement de l'acné
WO2018195415A1 (fr) * 2017-04-21 2018-10-25 Phi Therapeutics, Inc. Compositions comprenant des bactériophages de propionibacterium acnes destinées au traitement de l'acné

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017200873A1 (fr) * 2016-05-15 2017-11-23 The Regents Of The University Of California Compositions et méthodes pour le traitement de l'acné
WO2018195415A1 (fr) * 2017-04-21 2018-10-25 Phi Therapeutics, Inc. Compositions comprenant des bactériophages de propionibacterium acnes destinées au traitement de l'acné

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Evaluacion del efecto aditivo de bacteriófagos contra Cutibacterium acnes e isotretinoina en unmodelo de cultivo celular", 2022. 2° JORNADAS LATINOARNERICANAS DE BACTERIÓFAGOS 22 Y, 22 November 2022 (2022-11-22), XP093314753, Retrieved from the Internet <URL:https://unpaz.edu.ar/sites/default/files/inline-files/LIBRO%20RES%C3%9AMENES%20%281%29.pdf> *
CAMACHO RODRIGUEZ, L. T. ET AL., EVALUACION DEL EFECTO ADITIVO DE BACTERIÓFAGOS CONTRA CUTIBACTERIUM ACNES E ISOTRETINOÍNA EN UN MODELO DE CULTIVO CELULA R, 6 July 2023 (2023-07-06), Retrieved from the Internet <URL:https://repositorio.uniandes.edu.co/entities/publication/bc246244-23ef-4d80-95a8-b399dd4f150c> [retrieved on 20250123] *

Also Published As

Publication number Publication date
CO2023015253A1 (es) 2024-02-15

Similar Documents

Publication Publication Date Title
Mao et al. Realizing highly efficient sonodynamic bactericidal capability through the phonon–electron coupling effect using two‐dimensional catalytic planar defects
Lam et al. Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers
Yu et al. Ag-Conjugated graphene quantum dots with blue light-enhanced singlet oxygen generation for ternary-mode highly-efficient antimicrobial therapy
Chowdhury et al. Multivalent gold nanoparticle–peptide conjugates for targeting intracellular bacterial infections
Lei et al. Antibacterial photodynamic peptides for staphylococcal skin infection
Pantarotto et al. Solid-phase synthesis of fullerene-peptides
Mohid et al. Application of tungsten disulfide quantum dot-conjugated antimicrobial peptides in bio-imaging and antimicrobial therapy
US20220112469A1 (en) Targeted Phage for Bacterial Detection and Destruction
He et al. TO17: A teleost antimicrobial peptide that induces degradation of bacterial nucleic acids and inhibits bacterial infection in red drum, Sciaenops ocellatus
Mocan et al. Selective laser ablation of methicillin-resistant staphylococcus aureus with IgG functionalized multi-walled carbon nanotubes
Parasion et al. Isolation and characterization of a novel bacteriophage φ4D lytic against Enterococcus faecalis strains
Alabresm et al. Nanotargeting of resistant infections with a special emphasis on the biofilm landscape
Zhang et al. Quaternized carbon dots with enhanced antimicrobial ability towards Gram-negative bacteria for the treatment of acute peritonitis caused by E. coli
Hao et al. Impact of carbondiimide crosslinker used for magnetic carbon nanotube mediated GFPplasmid delivery
Zhang et al. Therapeutic evaluation of the Acinetobacter baumannii phage Phab24 for clinical use
Zhao et al. Enriching and Smart Releasing Curcumin via Phenylboronic Acid‐Anchored Bioinspired Hydrogel for Diabetic Wound Healing
Wang et al. Ta4C3 Nanosheets as a Novel Therapeutic Platform for Photothermal‐Driven ROS Scavenging and Immune Activation against Antibiotic‐Resistant Infections in Diabetic Wounds
Zheng et al. Poly (l-ornithine)-grafted zinc phthalocyanines as dual-functional antimicrobial agents with intrinsic membrane damage and photothermal ablation capacity
Ringaci et al. Phage-mimicking nanoagents for rapid depolymerase specificity screening against multidrug resistant bacteria
Xu et al. Turning Waste into Treasure: Functionalized Biomass‐Derived Carbon Dots for Superselective Visualization and Eradication of Gram‐Positive Bacteria
WO2025099684A1 (fr) Phage fonctionnalisé pour le traitement de l&#39;acné
Wang et al. Characterization of an Escherichia coli phage Tequatrovirus YZ2 and its application in bacterial wound infection
Mansoor et al. Topical polyethylene glycol-phage ointment as a therapy to treat burn-wound infection using mice model
Alharbi et al. Novel circular antimicrobial peptides to combat a critical listed bacterial pathogen multi drug resistant Acinetobacter baumannii
Quan et al. Peptide‐Enhanced Bioactive Hydrogel Combined with Photodynamic‐Phage Synergistic Antibacterial Therapy System Accelerates Infected Wound Healing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24888194

Country of ref document: EP

Kind code of ref document: A1